An independent study conducted in CB from 134 premature infants evaluated the potential of interleukin-6 (IL-6), its receptor IL-6R, soluble gp130, and matrix metalloproteinase 9 (MMP-9) as biomarkers of BPD. This evidence concerns the gene MMP9 and bronchopulmonary dysplasia.